|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab : Pharmacokinetic and pharmacodynamie rationale for dosing 显示文摘 | Fracasso PM Burris H 3rd Arquette MA | 2007 | Clin Cancer Res2007，13，3： | 1 |
| 2 | A phaseⅠstudy with neratinib(HKI-272),an irreversible pan Erb B receptor tyrosine kinase inhibitor,in patients with solid tumors显示文摘 | Wong KK Fracasso PM Bukowski RM | 2009 | Clin Cancer Res2009，15，7： | 1 |
| 3 | Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma:a gynecologic oncology group study显示文摘 | BRADY MF MOORE DH | 2001 | J Clin Oncol2001，19，12： | 1 |
| 4 | A phaseⅠstudywith neratinib(HKI-272),an irreversible pan ErbB receptortyrosine kinase inhibitor,in patients with solid tumors显示文摘 | Wong KK Fracasso PM Bukowski RM | 2009 | ClinCancer Res2009，15，： | 1 |
| 5 | A phase Ⅰ study with oeratinib (HKI-272) ,an irreversible pan ErbB receptor tyrosine kinase inhibitor,in patients with solid tumors 显示文摘 | Wong KK Fracasso PM Bukowski RM | 2009 | Clin Cancer Res2009，15，7： | 1 |
| 6 | Phase Ⅰ and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel,Taxoprexin ,in resistant solid tumor malignancies显示文摘 | Fracasso PM Picus J Wildi JD | 2009 | Cancer Chemother Pharmcol2009，63，3： | 1 |
| 7 | Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix:a gynecologic oncology group study 显示文摘 | Fracasso PM Blessing JA Wolf J | 2003 | Gynecol Oncol2003，90，1： | 1 |
| 8 | Phase II evaluation ofoxali- platin in previously treated squamous cell carcinoma of thecervix: a gynecologic oncoiogy group study 显示文摘 | Fracasso PM Blessing JA Wolf J | 2003 | Gynecol Oncol2003，90，1： | 1 |
| 9 | Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer:a gynecologic group study 显示文摘 | Fracasso PM Blessing JA Morgan MA | 2003 | J Clin Oncol2003，21，15： | 1 |
| 10 | Phase II study of Oxaliplatin in platinum - resistant and refractory ovarian cancer : a Gynecologic Oncology Group study 显示文摘 | Fracasso PM Blessing JA Morgan MA | 2003 | J Clin Oncol2003，21，14： | 1 |
| 11 | Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: a gynecologic oncology group study 显示文摘 | Fracasso PM Blessing JA Wolf J | 2003 | Gynecol Oncol2003，90，1： | 1 |
| 12 | Phase II study of oxali- platin in platinum-resistant and refractory ovarian cancer: a Gyneco- logic Oncology Group study显示文摘 | Fracasso PM Blessing JA Morgan MA | 2005 | J Clin Oncol2005，21，14： | 1 |
| 13 | A phase 1 escalating single-dose and weekly fixed-dose study of cctuximab:pharmacokinetic and pharmacodynamic rationale for dosing显示文摘 | Fracasso PM Burris H Arquette MA | | 0，，03： | 1 |
| 14 | Overexpression of the multidrug resistance-associated protein(MRP) gene in vincristine but not doxorubicin-selected multidmg-resistant murine显示文摘 | Slapak CA Fracasso PM Martell RL | 1994 | Cancer Res1994，54，： | 1 |
| 15 | Phase Ⅱ evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix:a gynecologic oncology group study显示文摘 | Fracasso PM Blessing JA Wolf J | 2003 | Gynecol Oncol2003，90，1： | 1 |
| 16 | A phase I study with neratinib ( HKI-272 ), an irreversible pan ErbB recep- tor tyrosine kinase inhibitor, in patients with solid tumors 显示文摘 | Wong KK Fracasso PM Bukowskietal RM | 2009 | Clinical Cancer Research2009，15，7： | 1 |
| 17 | A phase 1 escalating single-dose and weekly fixed-dose study o! cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing 显示文摘 | Fracasso PM Burris H 3rd Arquette MA | 2007 | Clin Cancer Res2007，13，3： | 1 |
| 18 | A phase I study with neratinib ( HKI-272 ), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors 显示文摘 | Wong KK Fracasso PM Bukowski RM | 2009 | Clin Cancer Res2009，15，7： | 1 |
| 19 | HKI - 272, an irreversible pan ErbB receptor tyrosine kinase inhibitor: preliminary phase 1 results in patients with solid tumors 显示文摘 | Wong KK Fracasso PM Bukowski RM | 2006 | J Clin Oncol2006，24，18： | 1 |
| 20 | Phase Ⅰstudy of pegylated liposomal doxorubicin and the multidrug-resistance modulator,valspodar显示文摘 | Fracasso PM Blum KA Ma MK | 2005 | Br J Cancer2005，93，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员